EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese ...
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...
FierceBiotech4d
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches
Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...
Capricor Therapeutics Poised for Growth with Expanded Deramiocel Partnership and Positive Phase 3 Outlook
Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
The Pharma Letter4d
Capricor rises as it expands deal with Nippon Shinyaku
US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the ...
Capricor Collaborates With Nippon Shinyaku For European Expansion Of Deramiocel For DMD; Stock Up
(RTTNews) - Capricor Therapeutics, Inc. (CAPR), Tuesday announced a deal with Japan-based Nippon Shinyaku Co., Ltd., to commercialize and distribute deramiocel in Europe, which is used for the ...
Capricor Therapeutics Shares Rise After Deramiocel Deal With Nippon Shinyaku
Capricor will receive an upfront payment of $20 million subject to execution of the definitive agreement, and there are potential additional development and sales-based milestone payments to Capricor ...
ETF Daily News3d
Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at Maxim Group
Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The company has a market cap of $163.73 million, a price-to-earnings ratio of -5.89 and a beta of 3.92.